



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Cudetaxestat

Item No. 38789

CAS Registry No.: 1782070-21-6
Formal Name: 3-[[2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl]thio]-2-fluoro-benzoic acid
MF: C₂₁H₁₅Cl₂F₂N₃O₂S
FW: 482.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cudetaxestat is supplied as a solid. A stock solution may be made by dissolving the cudetaxestat in the solvent of choice, which should be purged with an inert gas. Cudetaxestat is soluble in DMSO.

Description

Cudetaxestat is an inhibitor of autotaxin (IC₅₀ = ≤0.5 μM), also known as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2).^{1,2} It reduces migration of MDA-MB-435 melanoma cells (IC₅₀ = 15 nM).² Cudetaxestat reduces blood glucose levels in a glucose tolerance test, as well as baseline blood glucose levels, in mice fed a high-fat diet when administered at a dose of 15 mg/kg twice per day for two days.¹ It reduces liver fibrosis in mice fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAA/HFD) as a model of liver fibrosis when administered at a dose of 10 mg/kg.² It also reduces colon ulcer area and increases colon length in mouse models of acute and chronic ulcerative colitis, respectively.

References

1. Evans, J.F. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor. *Pharmakea, Inc.* **US009051320B1** (2015).
2. Bain, G., Evans, J.F., Hutchinson, J.H., *et al.* Autotaxin inhibitors and uses thereof. *Sabre Therapeutics, LLC.* **US010632104B2** (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/18/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM